Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib

Leukemia Research

Volumn 28, Issue SUPPL. 1, 2004, Pages 75-77

  Avery, S ^a   Nadal, E ^a   Marin, D ^a   Olavarria, E ^a   Kaeda, J ^a   Vulliamy, T ^a   Brito Babapulle, F ^b   Goldman, J M ^a   Apperley, J F ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

CML; Cytogenetic response; Imatinib; Lymphoid transformation

Indexed keywords

BCR ABL PROTEIN; BUSULFAN; HYDROXYUREA; IMATINIB; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

AGED; ANAMNESIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; BLAST TRANSFORMATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY TEST; LYMPHOID CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; STEM CELL; TREATMENT OUTCOME;

EID: 1342300622     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.10.019     Document Type: Article

References (8)

1. O'Brien S.G., Guilhot F., Larson R.A., Gattman I., Baccarani M., Cervanteset al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348:2003;994-1004.
2. Hughes T.P., Kaeda J., Branford S., Rudski Z., Hochhaus A., Hensley M.L.et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349:2003;1423-1432.
3. Bose S., Chowdhry V.P., Saxena R., Kucheria K. Lymphoid blast crisis during complete cytogenetic remission following interferon-alpha and hydroxyurea therapy. Acta Haematol. 98:1997;155-159.
4. Cullis J.O., Marks D.I., Schwarer A.P., Barrett A.J., Hows J.M., Swirsky D.M.et al. Relapse into blast crisis following bone marrow transplantation for chronic phase chronic myeloid leukaemia: a report of five cases. Br. J. Haematol. 81:1992;378-382.
5. Kaeda J., Chase A., Goldman J.M. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol. 107:2002;64-75.
6. Bhatia R., Holtz M., Niu N., Gray R., Snyder D.S., Sawyers C.L.et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 101:2003;4701-4707.
7. Graham S.M., Jørgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L.et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 99:2002;319-325.
8. Johnson R.J., Hillmen P. Paroxysmal nocturnal haemoglobinuria: nature's gene therapy? Mol. Pathol. 55:2002;145-152.